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Supplementary Figure 1. Probe and patient selection rationale for multivariate analysis in
human breast and pancreatic cancer patient datasets.
(a) Expression levels of three probes for stromal FAK (PTK2). Expression for tumour stroma and
normal stroma were indicated by black and green circles, respectively. Probe 3 (Agilent-012391
Whole Human Genome Oligo Microarray G4112A, platform GPL1708. Agilent feature number,
30462) had the lowest expression levels in tumour stroma, thus was excluded from our analysis. For
main Figure 1a, we show data using Probe 1 (PTK2_1, Agilent feature number, 4302). N=59,
including stromal samples derived from 53 primary breast tumours (black circles) and 6
morphologically normal stroma (green circles). The box and whisker plot - box denotes the
interquartile range (IQR, Q1 25th percentile – Q3 75th percentile), and whisker denotes the
maximum (Q3 + 1.5*IQR) and minimum (Q1 – 1.5*IQR). (b) KM plot using PTK2 probe 2
(Agilent feature number, 11888) with overall survival (OS). For survival analysis, the Cox
proportional hazards (Coxph) regression analysis was performed, and the log rank p-value was
shown. (c, d) Identification of tumour samples with activated stroma in Stratford et al. pancreatic
cancer patient data set (n=102). (c) In order to select the patients with activated stromal signatures,
non-negative matrix factorisation (NMF) was performed based on the stroma signature from Moffitt
et al., and cluster number k=3 provided the best clustering solution according to the Cophenetic
Coefficient score. (d) Expression heatmap of stroma signature across all 102 pancreatic cancer
samples. Samples with activated stroma (n=54) were identified with the high level of expression for
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Supplementary Figure 2. Characterisation of the FSP-Cre+;FAKfl/flmice shows no apparent gross
defects but depletion of FAK in CAFs.
(a) Offspring genotypes after breeding FSP-Cre+;FAKfl/+males with FSP-Cre-;FAKfl/fl females follow
normal Mendelian ratios. Bar charts show percentage of offspring genotypes. n = 37 FSP-Cre-;FAKfl/fl
(21.9%), 46 FSP-Cre+;FAKfl/fl (27.2%), 40 FSP-Cre-;FAKfl/+ (23.7%), 46 FSP-Cre+;FAKfl/+ (27.2%).
Body weights of the 30-day old female FSP-Cre-;FAKfl/fl and FSP-Cre+;FAKfl/flmice. Bar chart shows
mean mouse weight (g) ± s.e.m. n = 6 FSP-Cre-;FAKfl/fl and 6 FSP-Cre+;FAKfl/fl mice. Gender
distribution of the offspring after breeding FSP-Cre+;FAKfl/flmales with FSP-Cre-;FAKfl/fl females is
normal. Bar chart shows the number of mice. n = 85 males and 84 females. (b) H&E stained sections of
spleen, kidney and liver from non-tumour burdened FSP-Cre+;FAKfl/fl and FSP-Cre-;FAKfl/fl mice
showed no gross differences in basic morphology. N=3 slides/organ/genotype. (c)Western blot analysis
to assess the purity of primary fibroblast cultures. TB32048 pancreatic cancer cell line, primary lung
endothelial cells and primary brain pericytes are used as controls. E-cadherin and endomucin were not
expressed in fibroblast preps whilst they were positive for the tested markers of fibroblasts PDGFR-β
and FSP-1. N=1 TB32048, lung endothelial cell and brain pericyte prep and n=3 fibroblast preps from
3 mice. (d)Western blot analysis of epithelial cell lysates from breast tumours grown in MMTV+;FSP-
Cre+; FAKfl/fl and MMTV+;FSP-Cre-; FAKfl/fl mice show no change in FAK expression; n=4
MMTV+;FSP-Cre-; FAKfl/fl cell preps, n=3 MMTV+;FSP-Cre+; FAKfl/fl cell preps. Bar chart shows
mean densitometric readings ± s.e.m. Two-sided Student’s t-test. (e) Flow cytometric analysis of
tdTomato; MMTV+;FSP-Cre+ tumours indicate that 94.8% of tdTomato+ cells are CD45- (ie
fibroblasts) whilst 4.3% of tdTomato+ cells are CD45+. (f, g) Western blot analysis of macrophages
from either non-tumour bearing (nt) FSP-Cre+; FAKfl/fl and FSP-Cre-; FAKfl/fl or tumour bearing (T)
MMTV+;FSP-Cre+; FAKfl/fl and MMTV+;FSP-Cre-; FAKfl/flmice show no change in FAK expression.
HSC-70 acts as a loading control. Bar chart represents densitometric reading, means + s.e.m. n=3
independent preparations of macrophages. (h) FSP-Cre+;FAKfl/fl and FSP-Cre-;FAKfl/fl mice were
treated with bleomycin to induce lung fibroblast activation in vivo followed by primary fibroblast
isolation. Western blot analysis revealed elevated FSP-1 expression in both genotypes after activation
in vivo. Activated lung fibroblasts showed reduced expression of FAK when cells were isolated from
FSP-Cre+;FAKfl/fl mice. Expression levels of Pyk2 in activated fibroblasts were not significantly
different between genotypes. Bar charts show mean densitometry (AU) ± s.e.m. n = 3 fibroblast
preparations per genotype. HSC70 was used as a loading control.
(i)Western blot analysis of CAF lysates isolated from breast tumours in MMTV+;FSP-Cre+;FAKfl/fl and MMTV+;FSP-
Cre-;FAKfl/flmice show a significant depletion of FAK in CAFs isolated from MMTV+;FSP-Cre+;FAKfl/flmice. HSC-
70 acts as a loading control. Bar chart represents densitometric readings, mean + s.e.m., n= 3 independent replicates. (j)
RNAscope in situ hybridisation was performed on tumour sections to assess reduction of FAK expression levels in FSP-
1 positive CAFs in vivo. The number of purple dots representing FAK RNA transcripts was reduced in the cells which
expressed green dots, representing FSP-1 RNA transcripts, in tumours from MMTV+;FSP-Cre+; FAKfl/flmice but not
from MMTV+; FSP-Cre-;FAKfl/flmice. Scale bars (b) 50μm, (j) 50μm. (k, l) Late-stage tumour weights of (k) E0771
orthotopic breast tumours and, (l) TB32048 orthotopic tumours grown in FSP-Cre+;FAKfl/fl and FSP-Cre-;FAKfl/flmice.
Tumours grown in FSP-Cre+;FAKfl/flmice were significantly heavier compared to control tumours. Bar charts show
mean tumour weight ± s.e.m. n=15 E0771 and 10 TB32048 FSP-Cre-;FAKfl/fl tumours and 16 E0771 and 10 TB32048
tumours from FSP-Cre+;FAKfl/flmice. (m) Orthotopic breast tumour growth was similar in FSP-Cre+;non-floxed and
FSP-Cre-;non-floxed mice thus excluding the potential effect of Cre expression alone on tumour growth. Graph shows
mean tumour volumes ± (s.e.m). n = 7 FSP-Cre+;non-floxed and 7 FSP-Cre-;non-floxed mice tumours. *P<0.05,
**P<0.01, ****P<0.0001, nsd, no significant difference. Statistical analysis (d, f, g, h, i, k, l) two-sided Student's t-test
and (m) Two-way ANOVA.
































































































































































































































































































































































































































































































































































































































































































Supplementary Figure 3. FSP-Cre+; FAKfl/flmice show reduced TAMs, but no change in the
numbers and activation of T-lymphocytes as well as in the numbers of granulocytes, B-
lymphocytes and dendritic cells.
Flow cytometry analysis of fresh whole tumour cell suspensions showed that tumour associated
macrophages (F4/80+) are reduced in: (a) late-stage orthotopic breast (E0771; n=8 FSP-Cre-;
FAKfl/fl and 11 FSP-Cre+; FAKfl/fl) and pancreatic (TB32047; n=13 FSP-Cre-; FAKfl/fl and 14
FSP-Cre+; FAKfl/fl) tumours grown in FSP-Cre+; FAKfl/flmice and (b) spontaneous MMTV+;
FSP-Cre+; FAKfl/fl (n=10 FSP-Cre-; FAKfl/fl and 6FSP-Cre+; FAKfl/fl tumours) but not (c) early-
stage tumours (E0771; n=7 FSP-Cre-; FAKfl/fl and 8 FSP-Cre+; FAKfl/fl tumours. TB32048: n=4
FSP-Cre-; FAKfl/fl and 5 FSP-Cre+; FAKfl/fl tumours). Scatter plots show F4/80 +TAMs / mg
(tumour weight) and % of F4/80+ TAMs/CD45+ immune cells in MMTV model mean± s.e.m.
(d) Gr1+, CD3+ and CD19+ cell numbers are similar in E0771 (n=6 FSP-Cre-; FAKfl/fl and 7-10
FSP-Cre+; FAKfl/fl tumours), TB32048 (n=18-21 FSP-Cre-; FAKfl/fl and 21-23 FSP-Cre+;
FAKfl/fl) and MMTVPyMT (n=8-9 FSP-Cre-; FAKfl/fl and 5-6 FSP-Cre+; FAKfl/fl) tumours grown
in FSP-Cre+; FAKfl/fl and FSP-Cre-; FAKfl/flmice. (e) Numbers of activated T-lymphocytes are
unchanged in tumours grown in FSP-Cre+; FAKfl/fl and FSP-Cre-; FAKfl/fl mice. nsd, no
significant difference. Scatter plots represent mean ± s.e.m. n= 6-7 FSP-Cre-; FAKfl/fl and 4-5
FSP-Cr+-; FAKfl/fl MMTVPyMT tumours; n=6 FSP-Cre-; FAKfl/fl and 4-10 FSP-Cr+-; FAKfl/fl
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Supplementary Figure 4. Cell proliferation is unchanged in size-matched, early-stage tumours
grown in FSP-Cre-;FAKfl/fl and FSP-Cre+;FAKfl/fl mice and LC-MS analysis of pancreatic
tumours.
(a, b) Before tumour growth diverged significantly between genotypes (day 21 post-injection), early-
stage, size-matched tumours grown in FSP-Cre-;FAKfl/fl and FSP-Cre+;FAKfl/fl mice were
immunostained for Ki67 to compare cell proliferation between the two genotypes. (a, b)
Representative histological images and quantification of Ki67 staining in (a) breast E0771 and (b)
pancreatic TB32048 tumours. Scatter plots represent mean number of Ki67+ cells/per field ± s.e.m.
n= 23 TB32048 and 28 E0771 FSP-Cre-;FAKfl/fl and n=16 TB32048 and 30 E0771 FSP-Cre+;FAKfl/fl
high power fields (HPF) from n=3 (TB32048 and E0771 FSP-Cre-;FAKfl/fl) and 4 (TB32048 and
E0771 FSP-Cre+;FAKfl/fl) tumours. Scale bar in a and b, 100 mm. (c) FSP-Cre+;FAKfl/fl (n=4) and
FSP-Cre-;FAKfl/fl (n=6) mice bearing early-stage, size-matched TB32048 tumours were infused with
[U-13C] glucose for 15 minutes and LC-MS analysis of metabolites, extracted from frozen tumours,
was carried out. Bar charts show mean peak area (AU) ± s.e.m. (d) Extracellular flux analysis (Mito
Stress test) of primary FAK-depleted and WT-CAFs. Basal respiration and ATP production are
significantly increased in FAK-depleted CAFs; Bar chart shows mean OCR ± s.e.m. n=4 independent
experiments, 6 technical repeats for each genotype from the representative run. (e) OCR from
extracellular flux analysis of WT-CAFs treated with 5 μM FAK kinase inhibitor (PF-573,228) or
DMSO. Bar chart shows mean OCR ± s.e.m. n=2 independent experiments, 3 WT-CAF – inhibitor
and 4 WT-CAFS + inhibitor technical repeats for each treatment arm from separate primary CAF cell
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Ctnna1(S641); ** Catenin alpha-1 
Ctnnb1(S552); ** Catenin beta-1 
Itpr3(S1832); ** Inositol 1,4,5-trisphosphate receptor type 3 
Camkk2(S99); ** Calcium/calmodulin-dependent protein kinase kinase 2 
Camkk2(S511); ** Calcium/calmodulin-dependent protein kinase kinase 2 
Camkk2(S495); * Calcium/calmodulin-dependent protein kinase kinase 2 
Calm1 seq: 96 - 107  no mod * Calmodulin 
Calm1 seq: 92 - 107  no mod * Calmodulin 
Cdc42 seq: 154 - 163  no mod * Cell division control protein 42 homolog 
Cdc42ep4(S116); ** Cdc42 effector protein 4 
Cdc42bpa(S1638); * Serine/threonine-protein kinase MRCK alpha 
Rac3 seq: 154 - 163  no mod * Ras-related C3 botulinum toxin substrate 3 
Stat3 seq: 181 - 197  no mod *** Signal transducer and activator of transcription 3 
Stat3(Y705); * Signal transducer and activator of transcription 3 
Supplementary Figure 5. GSEA of metabolic pathways and analysis of chemokine expression
levels and differential signaling in malignant cells after exposure to CAF-FAK-depleted CM.
(a) GSEA identifies metabolic pathways that are significantly upregulated in epithelial cells in human
breast cancers with low stromal FAK when compared with epithelial cells in breast cancers with high
stromal FAK using KEGG (Kyoto Encyclopedia of Genes and Genomes) database. Data from Finak et
al dataset. (b-c) Images of whole Proteome cytokine arrays at high exposure (b) or low exposure (c).
Differentially regulated cytokines are highlighted. Images of dots used in the main figure are
highlighted in red boxes. N= 2 separate arrays. (d) qRT-PCR reveals enhanced Ccl7 and Ccl8
transcription in FAK-depleted CAF cells; Bar charts show mean mRNA expression ± s.e.m. n=2 WT
and 4 FAK-depleted CAF preps, 6 WT and 12 FAK-depleted technical repeats. (e) CCL7 expression is
inversely correlated with stromal FAK expression in breast cancer patients. (f) Representative images
of protein profiler arrays for Ccl6, Ccl12, Ccl11 and Pentraxin 3 from WT-CAFs isolated from
MMTV+;FSP-Cre-;FAKfl/fl mammary tumours treated with vehicle (DMSO) or 5 μM FAK inhibitor
for 24 hours. Bar charts show fold change in cytokine expression levels compared to vehicle controls
± s.e.m. n=4 individual dots/treatment. (g) qRT-PCR analysis reveals that Ccl6 and Ccl12 transcript
levels are enhanced in FAK-depleted CAFs. Ccl6, but not Ccl12, transcription is upregulated in WT-
CAFs after treatment with FAK kinase inhibitor; Ccl12 levels are reduced in FAK-depleted CAFs
following PI3K inhibitor (GDC-0941) treatment; Bar chart shows mean mRNA expression ± s.e.m.
n=6 technical repeats from two independent cell preparations. (h) qRT-PCR validation of siRNA
knockdown of Ccr1 and Ccr2 in E0771 cells; Bar chart shows mean Ccr1 mRNA expression ± s.e.m.
n=3 technical repeats/treatment. (i) Phosphoproteomics analysis identifies enhanced phosphorylation
of CTNNA1 and CTNNB1 supporting beta-catenin transactivation; changes in CaMKK2
phosphorylation, total calmodulin levels and Rho family of GTPases indicating activated GPCR
signalling; together with increased total STAT3 and pSTAT3 expression. *P<0.05,
**P<0.01,***P<0.001,****P<0.0001, nsd, no significant difference. Statistical analysis, two-sided
Student’s t-test.
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GO:0032007; P: negative regulation of TOR signalling cascade 
GO:0007188; P:G protein signalling, coupled to cAMP nucleotide second messenger
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Supplementary Figure 6. Assessing effects on BMDMs from FSP-Cre;FAKfl/flmice, effect of PKC-
inhibitor and efficacy and specificity of pharmacological inhibitors.
(a) BMDMs from non-tumour bearing FSP-Cre+; FAKfl/fl mice show no changes in glycolysis or
glycolytic capacity when compared with macrophages isolated from non-tumour bearing FSP-Cre-;
FAKfl/fl mice, n=3 independent experiments, scatter dots represent n=6 FSP-Cre-;FAKfl/fl , n=7 FSP-
Cre+;FAKfl/fl technical repeats from the representative run. (b) BMDMs from tumour-bearing
MMTV+; FSP-Cre+; FAKfl/flmice show enhanced glycolysis and glycolytic capacity when compared
with macrophages isolated from tumour bearing MMTV+; FSP-Cre-;FAKfl/fl mice, n=3 independent
experiments, scatter dots represent n=6 FSP-Cre-;FAKfl/fl, n=8 FSP-Cre+;FAKfl/fl technical repeats from
the representative run. ****P< 0.0001. Two-sided Students t-test. (c) BMDMs from MMTV+; FSP-
Cre-; FAKfl/flmice show enhanced glycolytic capacity and glycolytic reserve after treatment with FAK-
depleted CAF CM. n=3 independent experiments, scatter dots represent n=7 FSP-Cre-;FAKfl/fl , n= 6
FSP-Cre+;FAKfl/fl technical repeats from the representative run. (d) Extracellular flux analysis of
breast epithelial cells exposed to WT or FAK-depleted CAF CM in the presence of PKC-inhibitor; n=
11 individual cell preps, exposed to WT CM, n=5 exposed to FAK-depleted CM, n=6 exposed to FAK-
depleted CM + PKC inhibitor. Bar charts in a-d show mean ECAR ± s.e.m. (e) Evidence of in vivo
efficacy of CCR1i and CCR2i. Tumour bearing FSP-Cre+;FAKfl/flmice were treated with CCR1i and
CCR2i once daily from day 8 until the end of the study at day 34. Trough plasma levels, assessed on
blood samples taken 24 hours after the last dose, were greater than 10 x IC50 (see dotted red line) for
each compound, resulting in complete CCR1 and CCR2 receptor engagement by CCR1i and CCR2i,
respectively; Measure of centre shows the mean CCR1i plasma concentration (nM) from n=6 blood
samples from both CCR1i and CCR2i treated FSP-Cre+;FAKfl/fl mice. (f) CCR1i and CCR2i have
high specificity for their respective targets. Potency results are IC50 or A2 values from different assays
(binding, calcium flux, or migration) in buffer or serum using cells that express tested receptors. (g)
TB32048 tumour cells were treated with PKA inhibitor (KT5720) or PKC inhibitor (Go6983) and mass
spectrometry performed. Results showed significant alterations in several relevant downstream
signaling pathways. ****P<0.0001. (h) Primary fibroblasts were treated with PI3K inhibitor, GDC-
0941, and Western blot analysis showed a reduction in pAKT (s473). GAPDH acts as a loading
control. N= 2 independent cell preps. *P<0.05, **P<0.01, ***P<0.001, nsd, no significant difference.
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Supplementary Fig. 8, Demircioglu et al.
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Supplementary Figure 8. Gating strategy for FACs analysis. (a) Gating strategy for
identification of leukocytes by flow cytometry. Shown are representative images from the
analysis of cells from orthotopic breast tumours. TAMs are defined as CD45+CD11b+F4/80+;
Gr1+ cells as CD45+CD11b+F4/80-Gr1+,Ly6C+, CD19+; B cells as CD45+CD11b-F4/80-CD3-
CD19+; CD4 T cells as CD45+CD11b-F4/80-CD19-CD3+CD4+ and CD8 T cells as
CD45+CD11b-F4/80-CD19-CD3+CD8+. (b) Gating strategy for identification of T cell markers:
CD44, CD62L, CD69 and PD1.
